

Perspectives of next generation registry-cohort study -for target molecule and drug discovery

Chairs : Gen Sobue

Nagoya University Graduate School of Medicine

Shin'ichi Takeda

National Institute of Neuroscience, National Center of Neurology and Psychiatry

OC-03-1 Perspectives of ALS registry study

Gen Sobue

Nagoya University Graduate School of Medicine

OC-03-2 What we have learned from REMUDY during development of therapy of Duchenne muscular dystrophy

Shin'ichi Takeda

National Institute of Neuroscience, National Center of Neurology and Psychiatry

OC-03-3 Thousands Japanese Whole-genome Reference Panel and the Significance of Genome Cohort Project

Masao Nagasaki

Tohoku University, Tohoku Medical Megabank Organization, Department of Integrative Genomics, Division of Biomedical Information Analysis

OC-03-4 Implementation of "Clinical Sequencing" in Cancer Genome Medicine in Japan

Takashi Kohno

Div. Genome Biol., Natl Cancer Ctr Res Inst /Div. Genome TR, EPOC, Natl Cancer Ctr

Large scale multicenter studies of dementia

Chairs : Mikio Shoji

Department of Neurology, Hirosaki University Graduate School of Medicine,
Japan

Hiroshi Mori

Dept of Clinical Neuroscience, Osaka City University Medical school/Tamiya
Hospital, Japan**HT-01-1 The Dominantly Inherited Alzheimer Network (DIAN)- Japan**

Mie Hirohata

Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of
Medicine, Japan**HT-01-2 A4 study**

Takeshi Iwatsubo

The University of Tokyo, Neuropathology, Unit for Early and Exploratory Clinical
Development, Japan**HT-01-3 Japanese preclinical AD clinical study (AMED preclinical study)**

Hiroshi Mori

Dept of Clinical Neuroscience, Osaka City University Medical school/Tamiya Hospital, Japan

**HT-01-4 THE DOMINANTLY INHERITED ALZHEIMER NETWORK,
THE STUDY OF MUTATION CAUSED AD AND PREVENTION
TRIALS**

Randall Bateman

Washington University in St. Louis School of Medicine, USA

Co-hosted by: Japan Society for Dementia Research

Prediction of Parkinson's disease dementia

Chairs : Atsushi Takeda

National Hospital Organization Sendai-Nishitaga Hospital

Etsuro Mori

Department of Behavioral Neurology and Neuropsychiatry, United Graduate
School of Child Development, Osaka University**HT-03-1 Epidemiology of cognitive impairment in Parkinson's disease**

Kenji Wada-iso

Division of Neurology, Department of Brain and Neurosciences, Faculty of Medicine, Tottori
University**HT-03-2 The natural history of Lewy body disease: a consideration of
clinicopathological correlations**

Hiroki Fujishiro

Department of Psychiatry, Nagoya University Graduate School of Medicine

HT-03-3 Can we find clues of emergent dementia in Parkinson's disease using functional imaging?

Hitoshi Shimada

Department of Functional Brain Imaging Research (DOFI), National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST)

HT-03-4 Early diagnosis and treatment of dementia in Parkinson's disease

Toru Baba

Department of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine

HT-04 Hot Topics 04

En

May 24 (Thu) 15 : 20 ~ 17 : 20

Room9 (Royton Sapporo [Regent Hall] 2F)

Toward the early diagnosis and treatment of Progressive Supranuclear Palsy

Chairs : **Ikuko Aiba**

Department of Neurology, National Hospital Organization, Higashinagoya National Hospital, Japan

Takeshi Ikeuchi

Niigata University, Brain Research Institute, Japan

HT-04-1 Clinical Diagnosis of Progressive supranuclear palsy - The Movement Disorder Society Criteria

Günter Höglinger

German Center for Neurodegenerative Diseases Munich, Germany / Technical University Munich, Germany

HT-04-2 CSF Biomarkers for Diagnosis of PSP

Kensaku Kasuga

Department of Molecular Genetics, Brain Research Institute, Niigata University, Japan

HT-04-3 Neuroimaging Biomarkers for Diagnosis in PSP

Keita Sakurai

Tokyo Metropolitan Geriatric Hospital, Japan

HT-04-4 Tau targeted therapeutics for neurodegeneration: a critical role for the archetypical tauopathy PSP

Adam L. Boxer

University of California, San Francisco, USA

The direction of clinical, educational, research in the future medicine from the key persons of the administration.

Chairs : Masahisa Katsuno

Department of Neurology, Nagoya University Graduate School of Medicine

Yuko Saito

Department of Laboratory Medicine, National Center of Neurology and Psychiatry

S-06-1 The Future Direction of Medical Care System for Stroke

Yasufumi Gon

Cancer and Disease Control Division, Health Service Bureau, Ministry of Health, Labour, and Welfare

S-06-2 Clinical Training System for Medical Practitioners

Bunji Ishimaru

Medical Professions Division, Health Policy Bureau, Ministry of Health, Labour and Welfare

S-06-3 Strategy of AMED for rare disease research

Yoshihiko Furusawa

Japan Agency for Medical Research and Development

Basic and translational research of cerebral ischemia

Chairs : Yoshiki Yagita

Department of Stroke Medicine, Kawasaki Medical School

Takayoshi Shimohata

Department of Neurology and Geriatrics, Gifu University Graduate School of Medicine

S-07-1 Roles of Pericyte in brain ischemia

Tetsuro Ago

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University

S-07-2 VEGF ~A therapeutic target against hemorrhagic transformation after t-PA treatment~

Masato Kanazawa

Department of Neurology, Brain Research Institute, Niigata University

S-07-3 Neuroprotective effects of incretin (GLP-1) in acute ischemic stroke

Ryota Tanaka

Department of Neurology, Juntendo University

S-07-4 Development of novel therapeutic agents targeting post-ischemic inflammation

Munehisa Shimamura

Department of Neurology, Osaka University / Department of Health Development and Medicine, Osaka University

what's new in myoclonus

Chairs : Ritsuko Hanajima

Division of Neurology, Department of Brain and Neurosciences, Faculty of
Medicine, Tottori University

Yoshikazu Ugawa

Department of Neuro-regeneration, Fukushima Medical University /
Fukushima Brain Disease Center**S-08-1 Molecular genetic analysis of benign adult familial myoclonic epilepsy (BAFME)**

Hiroyuki Ishiura

Department of Neurology, The University of Tokyo Hospital

S-08-2 Spinal myoclonus

Nozomu Matsuda

Department of Neurology, Fukushima Medical University

S-08-3 EEG characteristics of myoclonus epilepsy

Riki Matsumoto

Department of Neurology, Kyoto University Graduate School of Medicine

S-08-4 Pathophysiology of myoclonus

Yoshikazu Ugawa

Department of Neurology, Fukushima Medical University

Medical Care Provision System based on the Intractable Disease Health Care Act ~Mission of Neurologists~

Chairs : Seiji Kikuchi

National Hospital Organization Hokkaido Medical Center

Masatoyo Nishizawa

Center for Integrated Human Brain Science, Brain Research Institute, Niigata
University**S-09-1 Structure of Medical System for Intractable Diseases in Japan**

Akiko Tanaka

Intractable/Rare Disease Control Division, Ministry of Health, Labour and Welfare

S-09-2 From the standpoint of hospital base of prefectural intractable diseases cooperation

Takanori Hazama

Department of neurology National Hospital Organization Osaka Minami Medical Center

S-09-3 From the hospital which serves as a base for each field of intractable disease treatment

Hideki Houzen

Department of Neurology, Obihiro Kosei Hospital

S-09-4 the National Center's viewpoint
En Kimura
National Center of Neurology and Psychiatry

S-10 Symposium 10

En

May 24 (Thu) 8:00 ~ 9:30

Room8 (Royton Sapporo [Empress Hall] 2F)

New approach to the cerebral small vessel disease

Chairs : Toshiki Mizuno
Department of Neurology, Kyoto Prefectural University of Medicine, Japan
Hidekazu Tomimoto
Department of Neurology, Mie University Graduate School of Medicine,
Japan

S-10-1 Acute stroke and stroke prevention management of cerebral small vessel disease

Andrew M. Demchuk
Calgary Stroke Program, University of Calgary, Canada

S-10-2 Neuropathological aspects of cerebral small vessel disease

Hidekazu Tomimoto
Mie University Graduate School of Medicine, Department of Neurology, Japan

S-10-3 Genetic background of the cerebral small vessel disease

Toshiki Mizuno
Department of Neurology, Kyoto Prefectural University of Medicine, Japan

S-10-4 Pre-clinical models of human cerebral small vessel disease: utility for clinical application

Masafumi Ihara
Department of Neurology, National Cerebral and Cardiovascular Center, Japan

S-11 Symposium 11

En

May 24 (Thu) 8:00 ~ 9:30

Room9 (Royton Sapporo [Regent Hall] 2F)

**Current topics in acute encephalitis update
- advance in diagnosis and treatment of autoimmune encephalitis**

Chairs : Satoshi Kamei
Division of Neurology, Department of Medicine, Nihon University School of
Medicine, Japan
Hideto Nakajima
Division of Neurology, Department of Internal Medicine IV, Osaka Medical
College, Japan

S-11-1 NMDA receptor encephalitis and other antibody-mediated disorders of the synapse

Josep Dalmau
ICREA, University of Barcelona and University of Pennsylvania, USA

S-11-2 Acute encephalitis associated with anti-myelin oligodendrocyte glycoprotein (MOG) antibodies

Juichi Fujimori

Department of Neurology, Tohoku Medical and Pharmaceutical University, Japan

S-11-3 Bickerstaff brainstem encephalitis

Susumu Kusunoki

Department of Neurology, Kindai University Faculty of Medicine, Japan

S-11-4 Limbic encephalitis with anti-NAE autoantibodies as a clinical subtype of Hashimoto's encephalopathy

Makoto Yoneda

Faculty of Nursing and Social Welfare Sciences, Fukui Prefectural University, Japan

Co-hosted by: Japanese Society for Neuroinfectious Diseases

S-12 Symposium 12

Jp

May 24 (Thu) 8:00 ~ 9:30

Room14 (Royton Sapporo [Pearl Hall AB] 20F)

Current essentials of treatment for neurological metabolic disorders

Chairs : **Mitsuharu Ueda**

Department of Neurology, Kumamoto University Hospital

Hiroaki Miyajima

First Department of Medicine, Hamamatsu University School of Medicine

S-12-1 Miglustat for Niemann-Pick Disease type C

Yoshio Sakiyama

Department of Neurology, Jichi Medical University, Saitama Medical Center

S-12-2 Early diagnosis and therapeutic strategy for FAP

Mitsuharu Ueda

Department of Neurology, Kumamoto University Hospital

S-12-3 Treatment strategies for Gaucher disease

Hiroyuki Ida

Department of Pediatrics, The Jikei University School of Medicine

S-12-4 Acute porphyria and human hemin

Hiroaki Miyajima

First Department of Medicine, Hamamatsu University School of Medicine

S-13 Symposium 13**Jp**

May 24 (Thu) 15 : 20 ~ 17 : 20

Room1 (Sapporo Geibunkan [Nitori Culture Hall] 1F)

Recent progress in clinical aspects of dementia

Chairs : Shun Shimohama

Department of Neurology, Sapporo Medical University School of Medicine

Mika Otsuki

Graduate School of Health Sciences, Hokkaido University

S-13-1 Clinical symptomatology of Alzheimer disease

Yasuhiro Nagahama

Kawasaki Memorial Hospital

S-13-2 Symptoms and image findings of degenerative dementia of non-Alzheimer's disease

Mika Otsuki

Graduate School of Health Sciences, Hokkaido University

S-13-3 Current and future treatments for Alzheimer's disease

Akira Tamaoka

Department of Neurology, Faculty of Medicine, University of Tsukuba

S-13-4 The status quo and the future on the treatment for non-AD type degenerative dementia disorders

Shun Shimohama

Department of Neurology, Sapporo Medical University School of Medicine

S-14 Symposium 14**Jp**

May 24 (Thu) 15 : 20 ~ 17 : 20

Room3 (Sapporo Geibunkan [Hourai] 3F)

Current status of secondary prevention of ischemic stroke

Chairs : Kazuo Kitagawa

Department of Neurology, Tokyo Women's Medical University School of Medicine

Takanari Kitazono

Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University

S-14-1 Prospects for the development of new antiplatelet agents against non-cardioembolic ischemic stroke

Kazuo Minematsu

National Cerebral and Cardiovascular Center

S-14-2 Antithrombotic therapy in non-cardiogenic stroke patients with atrial fibrillation

Hiroshi Yamagami

Division of Stroke Care Unit, National Cerebral and Cardiovascular Center

S-14-3 Risk Managements for Ischemic Stroke Prevention

Naohisa Hosomi

Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical & Health Sciences

- S-14-4** Current status of endovascular therapy for intra/extracranial artery occlusion
 Shinichi Yoshimura
 Department of Neurosurgery, Hyogo College of Medicine

S-15 Symposium 15

Jp

May 24 (Thu) 15 : 20 ~ 17 : 20

Room6 (Sapporo Geibunkan [Gyokuyou] 3F)

Development of new diagnostic and therapeutic methods in human prion diseases

Chairs : Masahito Yamada
 Department of Neurology and Neurobiology of Aging, Kanazawa University
 Graduate School of Medical Sciences
 Hidehiro Mizusawa
 National Center of Neurology and Psychiatry

- S-15-1** JACOP: Japanese Consortium of Prion disease. Road to Prion disease's clinical trials

Tadashi Tsukamoto
 Department of Neurology, National Center Hospital, National Center of Neurology and Psychiatry

- S-15-2** Classification and diagnostic criteria of prion diseases

Tsuyoshi Hamaguchi
 Department of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science

- S-15-3** Development of diagnostic method by detection of abnormal prion protein from biological sample

Katsuya Satoh
 Department of Locomotive Rehabilitation Science, Unit of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences

- S-15-4** Development of Therapeutics for Prion Diseases

Kazuo Kuwata
 United Graduate School of Drug Discovery and Medical Information Sciences

Co-hosted by: Japanese Society for Neuroinfectious Diseases

S-16 Symposium 16**Jp**

May 24 (Thu) 15 : 20 ~ 17 : 20

Room7 (Royton Sapporo [Castle] 1F)

Frontier of study for GBS and CIDP.-from molecular basis to cohort study-

Chairs : Yoshiyuki Mitsui

Center for General Medical Education and Clinical Training, Kindai University
Faculty of Medicine

Kenichi Kaida

Division of Neurology, Department of Internal Medicine, National Defense
Medical College**S-16-1 Eculizumab for Guillain-Barré syndrome: To overcome the disease**

Sonoko Misawa

Department of Neurology, Chiba University Graduate School of Medicine

S-16-2 Characteristics of Guillain-Barré syndrome in Japan; subtypes of GBS and prognostic tools

Yuko Yamagishi

Department of Neurology, Kindai University, Faculty of Medicine

S-16-3 Clinical and biological characteristics of anti-neurofascin 155 antibody-positive CIDP

Hidenori Ogata

Department of Neurology, Kyushu University Hospital

S-16-4 CIDP-J - the multicenter registry of Japanese CIDP patients

Shohei Ikeda

Department of Neurology, Nagoya University Graduate School of Medicine

Co-hosted by: Japanese Peripheral Nerve Society · The Japanese Society for Neuroimmunology

S-17 Symposium 17**En**

May 24 (Thu) 15 : 20 ~ 17 : 20

Room8 (Royton Sapporo [Empress Hall] 2F)

To pursue the best treatment of MG

Chairs : Hiroyuki Murai

Department of Neurology, International University of Health and Welfare,
Japan

Masakatsu Motomura

Medical Engineering Course, Nagasaki Institute of Applied Science, Japan

S-17-1 The treatment strategies of Japanese clinical guidelines for myasthenia gravis

Hiroyuki Murai

Department of Neurology, International University of Health and Welfare, Japan

S-17-2 An approach to optimal treatments for patients with myasthenia gravis

Ted M. Burns

University of Virginia, USA

S-17-3

Complement Inhibition in the Treatment of Myasthenia Gravis

James F. Howard Jr

The University of North Carolina at Chapel Hill, USA

S-17-4

How to achieve early treatment target in generalized myasthenia gravis

Kimiaki Utsugisawa

Department of Neurology, Hanamaki General Hospital, Japan